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Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham Maritime, Kent, United KingdomAcute myeloid leukaemia (AML) is a severe systemic malignancy this enzyme (the enzyme has three subunits – structural (A), regulatory
originated from self-renewing transformed immature myeloid precur-
sors. AML can often be a fatal disease since transformed cells operate
highly effective machinery which allows them to protect themselves
against induction of programmed cells death and also to suppress
anti-cancer activity of natural killer (NK) and cytotoxic T cells (CTCs)
thus evading immune attack [4, 6]. These biochemical networks act as
a “multilayer protection cover” for AML cells since even if they are
attacked by the immune cells, their killing becomes problematic due
to effectiveness of anti-apoptotic machinery. Therefore, it is crucially
important to understand themechanisms underlying functional activity
of anti-apoptotic biochemical networks operated by AML cells in order
to select optimal targets and design new drugs for successful and efﬁ-
cient therapy.
In the study published in this issue of EBioMedicine, Ruvolo and col-
leagues have demonstrated that two biochemical cell survival pathways
controlled by galectin-3 (a beta-galactoside-binding protein) and clus-
ter of differentiation (CD) 74 (a signalling receptor and a chaperone
for major histocompatibility complex type II proteins which are in-
volved in antigen presentation) are cross-linked in a biochemical pro-
tein network, which is associated with poor survival of AML patients
[7]. Importantly, this invaluable clinical study was performed using
samples obtained from a large number of AML patients (511 in total)
with newly diagnosed disease when malignant cells normally display
high pro-survival and immune evasion activities. The study reports
that galectin-3 expression is prognostic for poor survival rate of AMLpa-
tients. Survival rate of AML patients with galectin-3 positive malignant
cells was even lower when CD74-dependent signalling networks (in
particular, the one involving transmembrane receptor known as
CD44) were active. Intriguingly, the study reported galectin-3 to act as
a negative regulator of the protein phosphatase 2A (PP2A), the enzyme
involved in deactivation of several intracellular signalling cascades (see
below). It was shown that galectin-3 affects regulatory (B) subunit ofDOI of original article: https://doi.org/10.1016/j.ebiom.2019.05.025.
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This work is of great value for both basic and clinical AML research
since it is not just a report of cross-links between biochemical networks
but also a solid clinical veriﬁcation of the evidence obtained in basic
in vitro, ex vivo and in vivo studies, which can now be put together in
order to identify the best targets for complex anti-AML therapy.
AMLcellsoperateseveralpathwayswhichallowthemtodisablecyto-
toxic lymphoid cells (NK and CTCs; summarised in the Fig. 1). This in-
cludes implication of CD86-CTLA4 (cytotoxic T-lymphocyte-associated
protein 4) as well as ligands of programmed cell death protein (PD-L)-
PD1pathways [10]. Furthermore,AMLcells operate Tim-3 (T-cell immu-
noglobulinandmucin-domaincontainingprotein3)-galectin-9(another
member of galectin family of proteins, [4]) secretory pathwaywhich im-
pairsanti-AMLactivitiesofbothNKcells andCTCs.However, ifAMLcell is
attacked by cytotoxic lymphoid cells or subjected to action of endoge-
nous (e. g. pro-apoptotic cytokines) or exogenous (e. g. drugs) inducers
of apoptosis, it manages to survive with the help of galectin-3 and
CD74/CD44 signalling networkswhich appear to be connected [7].
From recent reports, we know that galectin-3 is capable to protect
mitochondria against defunctionalisation mainly via direct interaction
with proteins from Bcl (B cell lymphoma) -2 family including anti-
apoptotic Bcl-2 and pro-apoptotic Bax proteins [5,6,9]. As a result of
these interactions, Bcl-2 protects mitochondria and Bax loses its capa-
bility to cause mitochondrial dysfunction resulting in cytochrome c re-
lease followed by caspase-3/caspase cascade activation and apoptosis
(Fig. 1). Importantly, galectin-3 has NWGR (Asn-Trp-Gly-Arg) motif
speciﬁc to Bcl-2 family proteins which is necessary for homo- or
heterodimerisation of these proteins and thus is capable of interacting
with them [5,9]. Other galectin family members (for example galectin-
9), despite their ability to interact with defunctionalised mitochondria
in malignant cells [8], do not have this motif and thus do not display
such an activity.
CD74 and CD44 receptor alliance, activated by the ligand calledmac-
rophage migration inhibitory factor (MIF), is capable of activating Ras/
ERK (extracellular signal-regulating kinase) and phosphatidylinositol-
3 kinase (PI-3 K)/Akt pathways [1, 7]). Also, active CD74 can undergo in-
termembrane proteolytic cleavage and activate its intracellular domain
which displays functional activity. All these pathways activatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. Anti-apoptotic and immune evasion machineries operated by human AML cells. Galectins 3 and 9 are abbreviated as Gal-3 or Gal-9 respectively.
2 I.M. Yasinska, V.V. Sumbayev / EBioMedicine xxx (2019) xxxtranscription factors thus leading to expression of various genes, one of
which is Bcl-2 ([1], Fig. 1).
Tumour suppressor protein p53was reported to block expression of
galectin-3 by repressing transcription of its gene [2]. However, CD74/
CD44 activated by MIF, cause suppression of p53 activity [3] thus mak-
ing galectin-3 expression possible (Fig. 1). On the other hand, PP2A, the
enzymementioned above, targets crucial components of PI-3 K/Akt and
Ras/ERK pathways leading to loss of their activities. Ruvolo and Co-
Authors have shown that galectin-3 downregulates PP2A activity and
thus prevents de-activation of AML cell survival pathways ([7], Fig. 1).
So, in addition to its novelty, the work of Ruvolo and colleagues pro-
vides excellent clinical veriﬁcation of recently acquired basic knowl-
edge. Furthermore, the study clearly demonstrates that galectin-3 and
CD74 are promising targets for anti-AML therapy.
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